Scancell Holdings plc (LON:SCLP – Get Free Report)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 14.56 and traded as low as GBX 9.50. Scancell shares last traded at GBX 9.67, with a volume of 1,814,731 shares trading hands.
Scancell Stock Up 0.1%
The company has a market cap of £99.21 million, a PE ratio of -17.38 and a beta of 0.69. The business has a 50-day simple moving average of GBX 11.54 and a 200-day simple moving average of GBX 14.53. The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
